Ozempic (semaglutide): uses, dosing, side effects and cost
Ozempic is a once-weekly semaglutide injection made by Novo Nordisk and FDA-approved in 2017 for adults with type 2 diabetes. It lowers blood sugar and, in that group, reduces heart and kidney risk. It is not approved for weight loss; Wegovy is. Without insurance it costs $349 a month at most doses (NovoCare, checked 5 Oct 2026).
Quick facts
- Active ingredient
- Semaglutide, a GLP-1 receptor agonist (94% sequence match to human GLP-1)
- Maker
- Novo Nordisk Inc., Plainsboro, NJ
- FDA approval
- 2017 (initial U.S. approval); current label revised May 2026
- Approved for
- Adults with type 2 diabetes: blood sugar control, and cutting cardiovascular and kidney-disease risk in those with heart disease or CKD
- Form
- Multi-dose pen (2 mg, 4 mg or 8 mg per 3 mL) or, since the May 2026 label, a single-dose prefilled syringe
- How often
- Once a week, same day each week, any time, with or without food
- Dose strengths
- 0.25 mg (starting only), 0.5 mg, 1 mg, 2 mg; syringes come in 0.25, 0.5 and 1 mg
- Boxed warning
- Yes: thyroid C-cell tumors in rodents; not for anyone with a personal or family history of MTC or with MEN 2
- Self-pay price
- $349/month for 0.25–1 mg, $499/month for 2 mg; $199/month for a new patient's first 2 fills (NovoCare, checked 5 Oct 2026)
- Generic available?
- No FDA-approved generic. Compounded semaglutide is not generic Ozempic and is not FDA-approved
What it is
Ozempic is the brand name for semaglutide injection, a prescription medicine from Novo Nordisk for adults with type 2 diabetes. It belongs to the GLP-1 receptor agonist class, alongside Trulicity (dulaglutide) and Victoza (liraglutide). The FDA first approved it in 2017, and the current prescribing information was revised in May 2026, the revision that added a single-dose prefilled syringe to the long-standing multi-dose pen.
The same molecule is sold under other names for other purposes. Wegovy is semaglutide at higher doses for chronic weight management. Since May 2026 Novo Nordisk has also sold the Ozempic pill, oral semaglutide tablets of 1.5, 4 and 9 mg that reformulate the earlier Rybelsus strengths (Novo Nordisk, 1 May 2026). That tablet has its own label and dosing. This page covers the weekly injection only.
How it works
Semaglutide copies GLP-1, a gut hormone released after eating. According to the Ozempic label, it raises insulin release and lowers glucagon only when blood sugar is high, which is why it rarely causes low blood sugar on its own. It also slows early stomach emptying after meals, so glucose enters the blood more gradually.
In a 12-week study in the label, the 1 mg dose cut fasting glucose by 29 mg/dL and the two-hour after-meal reading by 74 mg/dL compared with placebo. Semaglutide binds tightly to albumin in the blood, which gives it a half-life of about one week. That is what makes once-weekly dosing possible, and it is also why the drug stays in the body for about 5 weeks after the last injection.
Approved uses
The Ozempic label lists three uses, all in adults with type 2 diabetes:
- Improving blood sugar control, alongside diet and exercise.
- Reducing the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) in those with established cardiovascular disease.
- Reducing the risk of sustained kidney-function decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease.
Ozempic is not approved for weight loss or for type 1 diabetes or children. Prescribing it for weight loss alone is off-label. Wegovy, the semaglutide brand approved for chronic weight management, is the on-label choice.
What the evidence shows
The label reports these results from Novo Nordisk's SUSTAIN and FLOW trials. All figures are averages across trial groups, not predictions for one person.
- Monotherapy, 30 weeks (SUSTAIN 1, NCT02054897): HbA1c fell 1.4 points on 0.5 mg and 1.6 points on 1 mg, versus 0.1 on placebo. Average weight change was −3.8 kg and −4.7 kg, versus −1.2 kg.
- 2 mg versus 1 mg, 40 weeks (SUSTAIN FORTE, NCT03989232): HbA1c fell 2.1 versus 1.9 points. Weight change (−6.4 kg versus −5.6 kg) was not statistically different.
- Heart outcomes (SUSTAIN 6): among 3,297 adults with type 2 diabetes and cardiovascular disease, 6.6% on Ozempic had a heart attack, stroke or cardiovascular death over a median 2.1 years, versus 8.9% on placebo (hazard ratio 0.74).
- Kidney outcomes (FLOW): in 3,533 adults with type 2 diabetes and CKD followed for a median 41 months, the kidney-and-cardiovascular composite occurred in 18.7% on 1 mg versus 23.2% on placebo (hazard ratio 0.76).
Dosing overview
Under the label, everyone starts on 0.25 mg once a week for 4 weeks, a starter dose meant to limit stomach side effects rather than to control blood sugar. The dose then goes to 0.5 mg. A prescriber can move to 1 mg, and later 2 mg (the maximum), when glucose targets are not met, with no less than 4 weeks between steps. People with type 2 diabetes and CKD are moved to a 1 mg maintenance dose. A missed injection can be taken within 5 days. Step-by-step tables, pen strengths and the missed-dose rule are on the Ozempic dosage page.
Side effects overview
Stomach and bowel effects are the most common, and most happen while the dose is being raised. In the label's placebo-controlled pool, nausea affected 15.8% on 0.5 mg and 20.3% on 1 mg, versus 6.1% on placebo. Vomiting reached 9.2% and diarrhea 8.8% on 1 mg. Overall, 3.1% to 3.8% stopped treatment because of digestive effects, against 0.4% on placebo.
The label's warnings cover pancreatitis, gallstones, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from dehydration, worsening diabetic eye disease, serious allergic reactions and aspiration under anesthesia. The full rate table and what to do about each effect are on the Ozempic side effects page.
Who should not take it
Three groups are ruled out by the label (contraindications): people who have had medullary thyroid carcinoma (MTC) or have a relative who has, people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and people who have had a serious allergic reaction to semaglutide or its ingredients.
It is not recommended with severe gastroparesis, and it has not been shown to be safe or effective in children. People with a history of pancreatitis or diabetic retinopathy need closer monitoring. The label advises stopping at least 2 months before a planned pregnancy because semaglutide takes weeks to clear. If any of these apply, ask your prescriber: "Given my history, is Ozempic the right GLP-1 for me, or is another option safer?"
Cost and access
The list price is $1,027.51 per pen (NovoCare list-price page, checked 5 Oct 2026). Novo Nordisk plans to cut it to $675 a month from 1 January 2027 (Novo Nordisk, 24 Feb 2026). Paying cash through NovoCare costs $349 a month for 0.25 mg to 1 mg and $499 for 2 mg, with new patients paying $199 for their first two fills of 0.25 or 0.5 mg through 31 December 2026 (NovoCare Ozempic price guide, checked 5 Oct 2026). With commercial insurance that covers it, the savings offer can bring the copay to $25, capped at $100 off a month; Medicare and Medicaid patients cannot use it.
Temi does not sell or fill Ozempic. Temi's physicians prescribe compounded semaglutide for weight loss, from $59.99 per 7.5 mg vial plus Temi's $39 prescription service, California pricing (usetemi.com/medications/compounded-semaglutide-injectable, checked 5 Oct 2026). Compounded semaglutide is not FDA-approved and is not a generic of Ozempic.
More on this medication
- Ozempic questions
Short answers to the questions people search most, each linked to the full answer.
- How to use the Ozempic pen
Step-by-step injection guide: flow check, dialing, the 6-second hold, sites and storage.
Frequently asked questions
Is Ozempic approved for weight loss?
No. Ozempic's FDA label covers adults with type 2 diabetes only: blood sugar control and lowering heart and kidney risk. Weight change was measured in its trials as a secondary result, for example 4.7 kg on average with 1 mg versus 1.2 kg on placebo over 30 weeks (Ozempic label). Wegovy is the semaglutide brand approved for chronic weight management. Temi's blog covers Ozempic for people without diabetes separately.
Is Ozempic the same as semaglutide?
Semaglutide is the active ingredient; Ozempic is Novo Nordisk's brand of semaglutide injection for type 2 diabetes. Wegovy and the Ozempic pill contain semaglutide too, at different doses and with different labels. Compounded semaglutide made by pharmacies uses the same molecule name but is not FDA-approved, is not reviewed for quality or effectiveness by the FDA, and is not a generic version of Ozempic.
Is there a generic Ozempic?
No. When we checked DailyMed on 5 October 2026, every semaglutide label listed came from Novo Nordisk or a repackager of its products; none was a generic. Products sold as "compounded semaglutide" are not generics either: pharmacies mix them, the FDA has not approved them, and their concentrations and added ingredients vary. Temi's blog has a separate explainer on the semaglutide patent timeline.
Can Ozempic be used for type 1 diabetes or in children?
No. The Ozempic label's three uses are all for adults with type 2 diabetes, and it states that safety and effectiveness have not been established in pediatric patients. Type 1 diabetes is not among the approved uses. Anyone with type 1 diabetes, or a parent asking about a child, should discuss approved options with an endocrinologist or the child's diabetes team.
How long does Ozempic stay in your system?
About 5 weeks after the last injection, according to the Ozempic label. Semaglutide's elimination half-life is roughly one week, so levels fall by about half each week. This long washout is why the label advises women to stop at least 2 months before a planned pregnancy, and why side effects can linger for a few weeks after stopping.
Who makes Ozempic, and where is it sold?
Novo Nordisk makes Ozempic and markets it in the U.S. from Plainsboro, New Jersey. It is sold with a prescription at retail pharmacies, and Novo Nordisk's own NovoCare Pharmacy delivers it to patients paying cash. Temi does not sell or fill Ozempic; this page is a reference.
Sources
- Ozempic (semaglutide) injection prescribing information and Medication Guide, Novo Nordisk, revised 05/2026 (checked October 5, 2026)
- Ozempic (semaglutide) injection label, DailyMed, National Library of Medicine (updated 1 June 2026) (checked October 5, 2026)
- Ozempic pill and pen price guide, NovoCare (checked October 5, 2026)
- Ozempic list price explained, NovoCare (checked October 5, 2026)
- Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus (press release, 24 Feb 2026) (checked October 5, 2026)
- Novo Nordisk's Ozempic pill soon to be available in the US (press release, 1 May 2026) (checked October 5, 2026)
- Compounded semaglutide injection, Temi (checked October 5, 2026)
- FDA's concerns with unapproved GLP-1 drugs used for weight loss (checked October 5, 2026)
- DailyMed search results for semaglutide, National Library of Medicine (checked October 5, 2026)
Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription.
Get started
Start online, and a licensed physician reviews your request
A short online questionnaire is the first step. No appointments and no insurance needed.
A licensed physician reviews every request. Nothing on this page is a prescription.